ArticleViruses2022
Characterization and Genomic Analysis of a Bacteriophage with Potential in Lysing Vibrio alginolyticus
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Genomic and Biological Characterization of a Broad-Host-Range KVP40-Like Bacteriophage vB_VpM-pA3B5 for Control of AHPND-CausingJournal of microbiology and biotechnology · 2026Article
- Isolation and characterization of Vibrio alginolyticus phage PV48 from Penaeus vannamei.Archives of virology · 2025Article
- Antivirulence Activity and Therapeutic Potential of JumboJournal of microbiology and biotechnology · 2025Article
- Uncommon Pathogens in Common Presentations: Genetic Profiling and Virulence Determinants ofInfectious disease reports · 2025Article
- Isolation and characterization of bacteriophages with lytic activity against multidrug-resistant non-typhoidal Salmonella from Nairobi City county, Kenya.BMC infectious diseases · 2025Article
- Isolation and identification of Klebsiella pneumoniae phage ΦK2046: optimizing its antibacterial potential in combination with chlorhexidine.Antimicrobial resistance and infection control · 2025Article
- Bacteriophage Therapy in Freshwater and Saltwater Aquaculture Species.Microorganisms · 2025Review
- Characterization and genomic analysis of a jumbo phage, PG216, with broad lytic activity against several Vibrio species.Archives of virology · 2025Article
- Article
- Isolation, characterization, and application of a novel Pseudomonas fluorescens phage vB_PF_Y1-MI in contaminated milk.Molecular genetics and genomics : MGG · 2024Article
- Distinct coral environments shape the dynamic of planktonic Vibrio spp.Environmental microbiome · 2023Article
- Characterization of vB_ValM_PVA8, a broad-host-range bacteriophage infectingFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vibrio alginolyticus is one of the major pathogens causing vibriosis to a variety of aquatic animals as well as bringing about severe food safety concerns. Nowadays, phage therapy has received increasing attention as an alternative to the antibiotics that have being limited for use in aquaculture industries. In this work, a potent bacteriophage, vB_ValM_PVA23 (PVA23), which efficiently infects pathogenic strains of V. alginolyticus, was isolated from sewage water and characterized by microbiological and genomic analyses. Based on the transmission electronic observation, the phage was characterized to be the Myoviridae family. It has a latent period of 10 min and a burst size of 203 PFUs/infected bacterium, and was stable over a broad pH range (5.0−11.0) and a wide temperature span (−80 °C to 60 °C), respectively. Genome sequencing results show that PVA23 has a 246,962-bp double-stranded DNA with a G + C content of 41.25%. The lab and plant shrimp farming trials demonstrated that phage preparation derived from PVA23 out-performed the chemical disinfectant iodine treatment in the prevention of V. alginolyticus propagation, and the phage application could rapidly yet significantly reduce the level of V. alginolyticus in the pond within 12 h, with negligible rebound observed. These results suggests that phage PVA23 has the potential to be used as an anti-V. alginolyticus agent in aquaculture industries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.